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ABSTRACT.
During the last decade, the fields of advanced and personalized therapeutics have
been constantly evolving, utilizing novel techniques such as gene editing and
RNA therapeutic approaches. However, the method of delivery and tissue
specificity remain the main hurdles of these approaches. Exosomes are natural
carriers of functional small RNAs and proteins, representing an area of
increasing interest in the field of drug delivery. It has been demonstrated that the
exosome cargo, especially miRNAs, is at least partially responsible for the
therapeutic effects of exosomes. Exosomes deliver their luminal content to the
recipient cells and can be used as vesicles for the therapeutic delivery of RNAs
and proteins. Synthetic therapeutic drugs can also be encapsulated into exosomes
as they have a hydrophilic core, which makes them suitable to carry water-
soluble drugs. In addition, engineered exosomes can display a variety of surface
molecules, such as peptides, to target specific cells in tissues. The exosome
properties present an added advantage to the targeted delivery of therapeutics,
leading to increased efficacy and minimizing the adverse side effects. Further-
more, exosomes are natural nanoparticles found in all cell types and as a result,
they do not elicit an immune response when administered. Exosomes have also
demonstrated decreased long-term accumulation in tissues and organs and thus
carry a low risk of systemic toxicity. This review aims to discuss all the advances
in exosome therapies in ophthalmology and to give insight into the challenges
that would need to be overcome before exosome therapies can be translated into
clinical practice.
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Introduction
Extracellular vesicles (EVs) is a broad
term given to lipid particles secreted
naturally by all cell types to facilitate
cell-to-cell interaction. These particles
are not self-replicated but instead are
produced within the cell. EVs are lipid
bilayer-encased extracellular structures
with a diameter that can range from 30
to 2000 nmand canbedivided into three
main types: exosomes,microvesicles and
apoptotic bodies (Borrelli et al. 2018)
(Table 1). EVs are known for their
natural cargo of RNAs, proteins and
lipids (Kastelowitz & Yin 2004). Over
the last decade, there has been increasing
interest in using EVs, in particular exo-
somes, in therapeutic and regenerative
nanomedicine.
Exosomes can be isolated from cul-
tured cells and body fluids, including
blood, saliva, urine, amniotic fluid and
breast milk (Allenson et al. 2017)
(Fig. 1). Their internal contents are
tissue-specific and can thus be used to
identify disease-specific biomarkers
(Roberson et al. 2011; Fais et al.
2016). Another area of interest is the
use of exosomes in regenerative medi-
cine. Researchers are currently explor-
ing the potential treatment of
degenerative disorders, such as Parkin-
son’s disease, by utilizing exosomes
isolated from mesenchymal stem cells
(MSC) (Vilaca-Faria et al. 2019; Zhao
et al. 2019). Moreover, exosomes can
act as an engineered drug vehicle to
allow for site-specific drug delivery.
Therefore, they can reduce the risk of
adverse side effects and improve the
therapeutic outcomes, as demonstrated
by their recent use in cancer therapy
(Frydrychowicz et al. 2014; Khalid
et al. 2017).
Many studies have highlighted the
variations in exosome cargo, particu-
larly miRNAs, and have proposed that
this might be responsible for the ther-
apeutic effects associated with EVs
(Sanz-Rubio et al. 2018). MiRNAs
are non-coding RNAs, 17-21 nucleo-
tides long, which are responsible for
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regulating gene expression at the post-
transcriptional level (Frydrychowicz
et al. 2014). There has been growing
interest in using exosomes and miR-
NAs in medicine, in particular ocular
diseases. Early efforts were made to
characterize some of the miRNAs pre-
sent in the aqueous humour as a
potential source of biomarkers for
Table 1. Classification of extracellular vesicles in terms of size, cargo and function.
Exosomes Microvesicles Apoptotic bodies
Diameter 30–100 nm 100–1000 nm 500–2000 nm
Cargo Proteins and nucleic acids
(mRNA, miRNA)




Function Intercellular communication Intercellular communication Phagocytosis and
recycling
A B C D
EXOSOME PROVIDER CANDIDATES
Drug and exosomes







Fig. 1. Study flowchart of exosome isolation, characterization, addition of therapeutic molecules and in vitro and in vivo testing in ophthalmic
diseases. 1. The exosomes are derived from either of these candidates: (A) Mesenchymal stem cells which originate from bone marrow, umbilical-cord
tissue or amniotic fluid; (B) Adipose tissue mesenchymal stem cells with positive biomarkers: Sca-1, CD44, CD105, MHC Ilow, CD71, CD73, CD90;
(C) Retinal astroglial cells; (D) Cell-free blood, plasma or biofluids. 2. Exosome isolation by adding ExoQuick to the sample that contains debris,
proteins, small vesicles and exosomes. 3. Ultrafiltration to remove debris proteins and small vesicles, and to extract exosomes from the sample. 4.
Exosome characterization (Nanosight, microscopy, biomarkers) to ensure they are exosomes. 5. Addition of therapeutic molecules to the exosomes. 6.
In vitro tests, for example, real-time qPCR for gene expression and cell viability. 7. In vivo tests, for example, local and systemic toxicity.
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disease prognosis and diagnosis, par-
ticularly in glaucoma (Dismuke et al.
2015). Furthermore, other studies have
established links between specific
miRNA cargos and therapeutic out-
comes (Safwat et al. 2018; Zhang et al.
2019).
This review aims to give a compre-
hensive detailed overview of the recent
studies that have utilized exosome
therapies in a variety of ophthalmic
diseases, including glaucoma, dry eye
disease, retinal ischaemia, diabetic
retinopathy, age-related macular
degeneration, uveitis and optic neu-
ropathy. We will also discuss the sev-
eral challenges that would need to be
overcome before exosome miRNA
therapies can be translated to patients
in the clinic.
Exosomes in Glaucoma
Glaucoma is the leading cause of irre-
versible blindness globally (Flaxman
et al. 2017). It is estimated that the
prevalence of glaucoma cases will rise
to 112 million by 2040, with current
cases affecting 76 million people in the
world (Tham et al. 2014). Glaucoma is
a degenerative disease that targets the
optic nerve and it is often associated
with elevated intraocular pressure
(Henson & Thampy. 2005). The ele-
vated intraocular pressure in glaucoma
leads to the loss of retinal ganglion cells
(RGCs) and blindness. RGCs convey
visual information from the retina to
the brain and once these cells are lost,
they cannot be regenerated (Almasieh
et al. 2012). Although the mechanism
by which these cells degenerate is not
well understood, studies have shown
that potential contributors include neu-
roinflammation, oxidative stress, lack
of neurotrophic factors, mitochondrial
dysfunction and axonal transport fail-
ure (Almasieh et al. 2012; Syc-Mazurek
& Libby 2019).
Exosomes extracted from ocular flu-
ids present an opportunity to screen for
notable biomarkers and can act as a
prospective diagnostic test to support
clinical decision-making. Dismuke
et al. (2015) analysed aqueous humour
samples and noted the presence of key
miRNAs, which included miR-486-5p,
miR-184, miR-204, miR-181a, miR-
191, miR-148a, miR-26a, miR-125a-
5p, let-7a and let-7b. The authors of
this study also reported that the two
most abundant miRNAs between
exosomes extracted from aqueous
humour and the conditioned media of
primary human trabecular meshwork
cells were miR-191 and miR-26a.
There have been many documented
pathways associated with glaucoma
and the impact that these can have on
the progression of the disease (Gau-
thier & Liu 2017). Liu et al. (2016)
found that the expression of miR-182
was significantly higher in exosomes
derived from human trabecular mesh-
work cells, and stated that miR-182
may be involved in the pathogenesis of
primary open-angle glaucoma through
regulation of aqueous humour dynam-
ics and intraocular pressure. A different
study by Lerner et al. (2020) focussed
on extracting exosomes from a non-
pigmented ciliary epithelium (NPCE)
cell line and studied their effects on the
expression of Wnt proteins in a trabec-
ular meshwork cell line. They cross-
matched their miRNA findings with
previously published aqueous humour
miRNA profiles and found 77 similar
miRNA profiles. The most abundant
miRNAs found in the NPCE exosomes
were miR-21, miR-638, let-7a, miR-100
and miR-16. Many of these miRNAs
have been found to regulate Wnt sig-
nalling in the trabecular meshwork.
Other identified miRNAs, such as miR-
29, miR-17 and miR-21, were also
found to modulate collagen produc-
tion. These findings suggest that exo-
somes derived for NPCE can modulate
the Wnt pathway in trabecular mesh-
work cells. However, further studies of
the mechanisms by which exosomes
modulate the Wnt pathway in the
trabecular meshwork are needed to
help identify new possible targets for
therapeutic approaches to treat pri-
mary open-angle glaucoma.
Recent studies have tried to over-
come the effects of glaucoma in animal
models using exosomes isolated from
bone marrow stem cells (BMSC)
(Table 2). A study by Mead et al.
(2018a) used rodents and divided them
into three groups. Group 1 (n = 5) had
rodents that were uninjured and
untreated, whereas Group 2 (n = 30)
and Group 3 (n = 35) had rodents
injured using intracameral microbeads
or laser photocoagulation of the tra-
becular meshwork, respectively, in
order to induce elevated intraocular
pressure. Both Groups 2 and 3 were
treated with BMSC exosomes or
fibroblast exosomes (control) in either
a weekly or a monthly intravitreal
injection plan. The authors reported
that the use of weekly and monthly
intravitreal BMSC exosomes promoted
neuroprotection of RGCs.
Furthermore, Mead et al. (2018b)
conducted another study using BMSC
exosomes on DBA/2J mice over a 12-
month period, administering monthly
intravitreal injections. They similarly
found that BMSC exosomes reduced
the number of degenerating axons in
the optic nerve. This group also carried
out an in vitro study using human
RGCs derived from human embryonic
stem cells (Mead et al. 2020). Their
results confirmed their previous find-
ings and showed that human BMSC
exosomes provided significant neuro-
protection to injured human RGCs
and promoted RGC survival. None of
the studies reported any adverse side
effects with the use of BMSC exo-
somes.
Although the in vitro and in vivo
studies have shown promising results
that BMSC exosomes may be a viable
therapeutic approach to treat glau-
coma in the future, a major challenge
is that the neuroprotective effects
appear to be short-term. The duration
of the first study in rodents only lasted
up to 56 days (Mead et al. 2018a) and
the second study’s long-term results
also demonstrated that RGC function
deteriorated over time. Moreover,
BMSC exosomes were not effective
after 6 months of treatment and pro-
vided no therapeutic benefit between 9
and 12 months (Mead et al. 2018b).
Repeated intravitreal injections are
thus likely to be needed every few
months to maintain the therapeutic
levels, which would increase the risk
of potential adverse effects and the
number of hospital visits needed for
glaucoma patients.
Mechanistically, Mead et al. (2018a)
have reported that the neuroprotective
effects might be related to the miRNA
cargo of BMSC exosomes, namely
MIR-106A-5P, MIR-486-5P, MIR-
144-5P, MIR-126-5P and MIR-100-
5P. Alternatively, the effects of BMSC
exosomes might be due to the modula-
tion of their mRNA cargo and TNFa
priming through increased levels of
pigment epithelium-derived factor
(PEDF) and vascular endothelial
growth factor (VEGF-A) (Mead et al.
2020). However, the miRNA neuro-
protective effects on RGCs are still
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Table 2. Exosome miRNA therapies in ophthalmology.
Disease References Species miRNAs Therapeutic effects Adverse effects
Glaucoma Mead et al.
(2018a)
Rodents The neuroprotective effects might be
related to the miRNAs from BMSC




neuroprotection of RGC and reduced






The effects might be related to the
miRNAs from BMSC exosomes
Human BMSC exosomes provided
neuroprotection to the injured RGC




Rats The effects of MSC exosomes might be
due to the modulation of their mRNA
cargo and TNFa priming through
increased levels of PEDF and VEGF-
AA
MSC exosomes stimulated RGC
survival resulting in neuroprotective






Humans The precise regulation role of MSCs has
not been fully defined
MScs can suppress the inflammatory
and fibrous processes in dry eye in









The effects of human MSC might be due
to the paracrine factors and miRNAs







The antiangiogenic effects of RAC
exosomes might be caused by their
multiple molecules (proteins, lipids,
mRNA, miRNA)








The effects of MSC exosomes might be












Rabbits The regenerative changes in the retina
might be associated with the increased
expression of miRNA-222
Adipose MSC exosomes induced repair
of diabetic retinal degeneration and





Rats miRNA-126 expression in MSC
exosomes might reduce retinal
inflammation by downregulating the
high-mobility group box 1 (HMGB1)
pathway




















Nil Potential increased wet AMD and
choroidal neovascularization




The effects of human MSC exosomes
might be due to their cargo which is
abundant in proteins and RNAs
Human MSC exosomes inhibited the
autoimmune response, protected the






Rats The therapeutic effects of MSCs in
suppressing inflammation correlated
with the TSG-6 mRNA level in MSCs
Human MSCs from different donors
varied in their therapeutic effects in
suppressing inflammation in vivo, and











The therapeutic effects might be caused
by specific miRNAs, namely miR-17-92
BMSC exosomes promoted
neuroprotection and neurogenesis of




largely unknown and will require fur-
ther investigation. Further studies
would also be beneficial regarding the
long-term efficacy of exosome therapy
and to determine whether these pre-
clinical results could be translated to
glaucoma patients in the future.
Exosomes in Dry Eye
Disease
Dry eye disease (DED), also known as
keratoconjunctivitis sicca, is a common
condition associated with tear film
disruption and damage of the ocular
surface. Even though the symptoms
can be varying, they can be generally
categorized into tear-deficient dry eyes
and evaporative dry eyes (Lemp et al.
2007). Current treatments vary from
the administration of artificial tears for
mild and moderate DED to the admin-
istration of autologous serum eye
drops and anti-inflammatory drugs
for severe cases (Pflugfelder et al.
2007). Chronic graft versus host disease
(cGvHD) is a condition that can occur
after bone marrow transplantation, as
the donor cells can view the recipient’s
body as foreign and attack it, causing
inflammation (Lee et al. 2003). The
cGvHD is characterized by dry eyes,
joint pain, rashes and shortness of
breath, with dry eyes being the most
common symptom affecting 40–76% of
patients (Lee et al. 2021).
MSCs have been considered as an
alternative therapeutic approach for
dry eyes in cGvHD. In a 2012 study
by Weng et al. (2012), the group
investigated the efficacy of MSCs for
the treatment of cGvHD-related dry
eye disease as the most important
clinical feature of MSCs is their
immunomodulatory role and their abil-
ity to assist in controlling inflammatory
diseases (Table 2). The authors con-
cluded that the infusion of MSCs
improved clinical symptoms in 54.6%
of the patients, presenting a promising
alternative treatment for dry eye dis-
ease.
Based on this study and the knowl-
edge that exosomes derived from
MSCs have many of the same
immunoregulatory properties as their
cells of origin, the same group regis-
tered for a phase 1/2 clinical trial in
December 2019 (NCT04213248). This
single-arm trial aimed to determine
whether umbilical MSC (UMSC)-
derived exosomes can alleviate dry eye
symptoms in patients with cGvHD and
to evaluate the clinical outcomes. The
patients will be treated with artificial
tears for 2 weeks, in order to establish
a baseline, followed by 10 µg/drop of
UMSC exosomes four times a day for
14 days. Disease indicators, such as the
amount of tear secretion, tear break
time and the degree of damage to
tissues, will be recorded and assessed
for 12 weeks after treatment.
To the best of our knowledge, this is
the first and only clinical trial utilizing
exosomes in ophthalmology. If success-
ful, this study will be a breakthrough
and proof of concept for the use of
exosomes as an alternative therapeutic
approach for the treatment of ocular
diseases. It has to be noted that the
estimated completion date for this trial
was May 2020, however it still remains
in the recruiting phase.
Exosomes in Retinal
Ischaemia
The retina is a light-sensitive tissue
forming the innermost layer at the
back of the eye and consists of pho-
toreceptors that absorb light impulses.
These light impulses then travel through
the optic nerve to the brain to process
the image seen through our eyes. For
the retina to function, it requires an
adequate supply of oxygen and nutri-
ents derived from the blood supply via
the central retinal artery. If the blood
supply is reduced, the retinal tissues can
become ischaemic, which then leads to
loss of vision. Several conditions can
cause retinal ischaemia, including dia-
betic retinopathy and retinal artery
occlusion (Minhas et al. 2012).
To study the protective effects of
MSC-derived exosomes in retinal
ischaemia, Mosseiev et al. (2017) used
12 male C57BL/6 mice in a 2-week
study and split them into three groups
(n = 4 mice in each group) (Table 2).
Mice in the first and second groups were
placed in a closed chamber at 75%
oxygen for 5 days to cause oxygen-
induced retinopathy. Mice in the first
group were then injected with saline,
whereas mice in the second group were
injected with exosomes derived from
human MSC. Mice in the third group
(control group) were kept in standard
room air and were injected with saline.
The authors reported that human MSC
exosomes were well-tolerated and had a
positive therapeutic effect on retinal
ischaemia, leading to a significant
reduction in retinal thinning and neo-
vascularization. They also suggested
that the therapeutic effects might be
due to the paracrine factors and miR-
NAs of human MSC exosomes (Mos-
seiev et al. 2017).
These findings were further sup-
ported by an earlier study by Hajra-
souliha et al. (2013) who used exosomes
from mice retinal astroglial cells (RAC)
to significantly suppress retinal vessel
leakage and to inhibit choroidal neo-
vascularization (CNV) in a laser-
induced C57BL/6 mice model. These
studies show that exosome therapy
could provide a more targeted thera-
peutic approach to the damaged tissue
and limit the treatment’s adverse effects.
The antiangiogenic effects might also be
Table 2 (Continued)
Disease References Species miRNAs Therapeutic effects Adverse effects
and tensin homolog (PTEN), an
important suppressor of RGC axonal






The most abundant miRNAs in human
UMSC exosomes are miRNA-21-5p,
miRNA-125b-5p, miRNA-23a-3p,
miRNA-100-5p and let-7f-5p
UMSC exosomes promoted RGC
survival and glial cell activation
Nil
BMSC = bone marrow stem cells; MSC = mesenchymal stem cells; RAC = retinal astroglial cells; RGC = retinal ganglion cells; UMSC = umbilical-
cord mesenchymal stem cells.
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related to the multiple molecules (pro-
teins, lipids, mRNA, miRNA) of RAC
exosomes (Hajrasouliha et al. 2013).
A more severe form of retinal ischae-
mia can occur if the retina becomes
detached from the retinal pigment
epithelium. Some of the consequences
of a retinal detachment include atrophy
of the photoreceptor cell layer, retinal
thinning and retinal pigment epithelium
alterations (Ghazi & Green 2002). A
study conducted by Ma et al. (2020)
used MSC exosomes from Sprague-
Dawley rats to study their effects in
retinal detachment. They found
that MSC exosomes were able to pre-
vent photoreceptor apoptosis following
retinal detachment in the rat model. The
MSC exosomes also promoted anti-
inflammatory effects and suppressed
inflammatory cytokine induction. Simi-
lar to the studies in glaucoma, this study
showed that exosome treatment had
beneficial neuroprotective effects (Mead
et al. 2020).
MSC exosomes represent a promis-
ing therapy for retinal ischaemia with
no adverse side effects reported in the
studies. However, further dose-response
studies are needed to determine the
mechanism of action and any potential
long-term treatment effects. Immuno-
genicity is also a potential concern for
clinical translation in patients. Interest-
ingly, (Mosseiev et al. (2017) used
human MSC exosomes on mice in their
study and found no immunogenicity
Mosseiev et al. (2017). However, it is
unknown if animal-derived exosomes
would be compatible with human retinal
disease models and whether exosomes
would need to be matched to specific
patients in clinical practice. Many of
these preclinical studies have been con-
ducted on animal models; however,
future studies will need to test whether
the same effect can be achieved when
using exosome therapies in humans.
Exosomes in Diabetic
Retinopathy
The prevalence of diabetes was over 3.9
million people in the UK in 2019
(Diabetes UK, 2020). Diabetic retinopa-
thy is a common complication of dia-
betes and is one of the leading causes of
blindness in the working-age population
(Wang & Lo 2018). Diabetic retinopa-
thy can be divided into two main types:
non-proliferative diabetic retinopathy
(NPDR) and proliferative diabetic
retinopathy (PDR). Clinical manifesta-
tions of NPDR are microaneurysms,
retinal haemorrhages and intraretinal
microvascular abnormalities, whereas
PDR is characterized by neovascular-
ization. Both types of diabetic retinopa-
thy can lead to diabetic macular oedema
(Stitt et al. 2016).
Recent studies utilizing exosome
miRNA therapy have shown promising
results in diabetic retinopathy
(Table 2). Safwat et al. (2018) induced
diabetes in a rabbit model using strep-
tozotocin intravenous injections. Exo-
somes were extracted from MSCs
isolated from rabbits’ adipose tissue
and were injected in the diabetic rab-
bits using intravenous, subconjunctival
or intraocular routes (Safwat et al.
2018). Interestingly, different routes of
exosome administration resulted in
different therapeutic effects on the
retina. Twelve weeks post-injection,
subconjunctival exosome treatment
restored the retina’s cellular compo-
nents, whereas intraocular exosome
treatment encouraged retinal regenera-
tion and formed well-defined layers like
those in a normal retina. Conversely,
systemic intravenous exosome treat-
ment increased retinal thickness with
an irregular ganglion layer. The
authors found an increased expression
of miRNA-222 in the retinal tissue of
the rabbits treated with exosomes and
proposed that MSC exosomes could
mediate regenerative changes in the
retina by transporting specific miRNAs
like miRNA-222 (Safwat et al. 2018).
Another study by Zhang et al. (2019)
showed that MSC exosomes overex-
pressing miRNA-126 were able to
reduce the retinal inflammation caused
by hyperglycaemia in a rat model. MSC
exosomes were isolated from the media
of human umbilical cord-derived MSCs,
followed by the transfer of miRNA-126.
The authors reported that the adminis-
tration of miRNA-126-expressing MSC
exosomes significantly reduced the
hyperglycaemia-induced expression of
the high-mobility group box 1
(HMGB1) pathway and the activity of
the NLRP3 inflammasome in human
retinal endothelial cells (Zhang et al.
2019). Although the results are promis-
ing with no adverse effects reported in
both studies, the role of MSC exosomes
and specific miRNAs in the process is
still unknown, and further studies will
be needed to explore this further. A
later study by Huang et al. (2018) also
found that in the mouse model, there
was an association with IgG-laden exo-
somes in diabetes that led to the activa-





Age-related macular degeneration (AMD)
is the leading cause of central vision loss in
the elderly population in the western
world. It was projected that in 2020, 196
million people were affected with AMD
and by 2040, the number is likely to
increase to 288 million (Wong et al. 2014).
AMD is a progressively chronic disease
on the central retina and there are 2 main
forms: dry AMD and wet AMD (also
known as neovascular AMD). Dry AMD
is characterized by drusen formation and
atrophy of the retinal pigment epithelium
layer (Arya et al. 2018), whereas choroidal
neovascularization in wet AMD leads to
the leaking of fluids, lipids and blood that
can cause fibrous scarring (Lim et al.
2012).
Studies have been carried out to
investigate the exosome cargo of retinal
pigment epithelium (RPE) cells in
order to develop innovative therapies
and to understand the mechanisms that
cause this disease. A study conducted
by Atienzar-Aroca et al. (2016) found
that stressed RPE cells release a high
quantity of exosomes containing
mRNA for VEGFR-1 and VEGFR-2.
These are receptors for VEGF that
play a vital role in new blood vessel
formation. Further work by this group
identified that VEGFR-2 is activated in
abnormal angiogenesis by receptors
released from RPE-derived exosomes.
In addition, the authors reported that
exosomes released from stressed RPE
cells promote autophagy, which fur-
thers the progression of AMD
(Atienzar-Aroca et al. 2018).
Kang et al. (2014) also looked into
identifying biomarkers for wet AMD
from exosomes derived from the aque-
ous humour of AMD patients and
from ARPE-19 cell line and identified
six proteins of interest. Elbay et al.
(2019) looked into extracting exosomes
from the blood serum of patients with
wet AMD (n = 70) and notably found
that the expression of miR-626 and
miR-485-5p was increased when com-
pared to control patients (n = 50)
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(Table 2). However, an underexpres-
sion of miR-885-5p when compared to
the control group was observed.
Although these miRNAs could act as
targets for future therapies, it cannot
be confirmed whether these markers
are the same for all forms of AMD.
The authors pointed out that their
sample size did not include subjects
with early AMD, and therefore, it
cannot be determined yet whether these
markers could be used for patients with
earlier stages of AMD or more subtle
signs of the disease.
Exosomes in Uveitis
Uveitis is a disease caused by inflam-
mation of the iris, ciliary body, vitre-
ous, retina or choroid (Seve et al.
2017). It can lead to irreversible visual
loss if not treated in a timely manner,
and current treatments include
immunosuppressive therapy and corti-
costeroids (Chen & Sheu 2017). Exo-
some therapy has also been explored as
a potential treatment in uveitis.
In one study, Bai et al. (2017) used
Lewis rats which were induced with
experimental autoimmune uveoretinitis
(Table 2). Human MSC exosomes were
shown to inhibit autoimmune response
in the rat model, thereby protecting the
retinal structure and rescuing retinal
function. The effects of human MSC
exosomes might be due to their cargo
which are abundant in RNAs and
proteins (Bai et al. 2017). The mecha-
nism through which human MSC exo-
somes can act as an immunosuppressant
remains unclear and will need to be
assessed in future studies.
Shigemoto-Kuroda et al. (2017) car-
ried out further work to support the
role of human MSC exosome therapy
in rat models. They found that the
therapeutic efficacy of MSCs in sup-
pressing inflammation correlated with
the mRNA level of TNF-a-simulated
gene 6 (TSG-6) in those MSCs. How-
ever, they reported that a challenge
with human MSC exosome therapy is
that exosomes are heterogeneous
depending on their source and envi-
ronment. Human MSC from different
donors varied in their therapeutic
effects in suppressing inflammation
in vivo, and some human MSC had
no positive therapeutic effect. This
could act as a major limitation of
exosome therapy in humans, as exo-
somes derived from a specific patient
may have limited or no therapeutic
effect. Exosomes could potentially be
donated from other patients and used
for treatment, but there is uncertainty
on whether this would elicit a deleteri-
ous immune response. The source of
exosomes thus needs careful consider-
ation when developing MSC exosome




Optic neuropathy or optic atrophy
refers to the pathological damage of
the optic nerve or its blood supply. It is
most commonly caused by optic neuri-
tis and ischaemic optic neuropathy and
can eventually lead to loss of vision
(Dworak & Nichols. 2014). Optic nerve
crush is an experimental disease model
used in research to induce optic neu-
ropathy. It leads to the loss of RGCs,
which can be useful to understand the
neuronal mechanisms and to develop
new therapies (Tang et al. 2011).
Crushing the optic nerve in the rodent
model leads to an abrupt loss of RGCs
after day 5, followed by a loss of 50%
and over 90% by day 7 and day 14,
respectively (Berkelaar et al. 1994).
Recent studies have looked at the
neuroprotective effects of exosome ther-
apies in optic neuropathy (Table 2).
Mead and Tomarev (2017) found that
BMSC exosomes promoted neuropro-
tection and neurogenesis of RGCs in
primary retinal cultures. The authors
also reported similar results in their
in vivo studies, which were done over
21 days following optic nerve crush in
Sprague-Dawley rats. As part of the
treatment plan, exosomes were injected
intravitreally every week after the optic
nerve crush. The rats treated with
BMSC exosomes only had a 30% loss
of RGCs, whereas untreated rats dis-
played 80-90% loss of RGCs after
21 days following the optic nerve crush.
BMSC exosomes promoted survival of
RGCs and regeneration of their axons,
and partially prevented RGC axonal
loss and RGC dysfunction. BMSC
exosomes contain several miRNAs,
particularly miR-17-92, which down-
regulate the expression of phosphatase
and tensin homolog (PTEN) and are an
important suppressor of RGC axonal
growth and survival (Zhang et al.
2017).
Pan et al. (2019) built on this study
and used 18 adult Wistar rats that were
divided into three groups. The first
group were uninjured, untreated rats.
The rats in the second group under-
went optic nerve crush and were
treated with exosomes derived from
umbilical-cord MSC (UMSC), whereas
the rats in the third group underwent
optic nerve crush and were treated with
saline. After three treatments with an
interval of 1 week, the authors found
that the UMSC exosomes significantly
promoted RGC survival and glial cell
activation compared to saline controls.
However, UMSC exosomes were not
able to promote axonal regeneration in
the optic nerve like the BMSC exo-
somes (Mead & Tomarev 2017). The
authors proposed that this could be
due to the differences in miRNA cargo
between BMSC exosomes and UMSC
exosomes. The five most abundant
miRNAs in human UMSC exosomes
were miRNA-21-5p, miRNA-125b-5p,
miRNA-23a-3p, miRNA-100-5p and
let-7f-5p (Fang et al. 2016), whereas
the five most abundant miRNAs in
BMSC exosomes were miR-143-3p,
miR-10b-5p, miR-486-5p, miR-22-3p
and miR-21-5p (Baglio et al. 2015).
These studies demonstrated that the
regular administration of BMSC exo-
somes had a beneficial neuroprotective
effect. However, further dose-response
studies will be required to determine
the optimum dosage and frequency of
treatment. Previous work in other dis-
ease models has shown that exosomes
do not exert any therapeutic effects
after six months (Mead et al. 2018).
Further studies to investigate whether
outcomes improve after long-term
treatment will need to be carried out
in the future. Moreover, since these
studies showed limited therapeutic
effects in the form of axonal regenera-
tion for optic nerve injuries, it would be
interesting to study the effects of exo-
somes from alternative sources and
whether they could further improve
the therapeutic effects.
Discussion
In recent years, there has been a
growing interest in developing exosome
therapies in ophthalmology. They are
considered natural novel therapeutic
agents largely due to their internal
contents, in particular, their unique
miRNA cargo. The studies discussed
7
Acta Ophthalmologica 2021
in this review highlight the therapeutic
effects of using exosomes extracted
from various sources and their ability
to induce desirable effects in overcom-
ing common eye diseases. However, the
studies did not conduct any experi-
ments to assess toxicity, which is an
important factor we must consider. We
have limited information on whether
there is any toxicity noted when admin-
istering exosome therapies in these
studies. Zhu et al. (2017) reported
minimal toxicity and immunogenicity
when administering sustained doses of
exosomes derived from HEK293T cells
in mice. However, it cannot be con-
cluded whether this would be the same
for all exosomes from various sources.
While there are current alternative
therapies looking into the use of lipid
nano-molecules and gene-based thera-
pies, one of the many challenges in
creating a new drug complex is creating
an efficient delivery system. Fortu-
nately, exosomes offer the ability to
be modified to allow specificity and due
to their small size, they can overcome
biological barriers that conventional
medications and gene therapies are
not able to do. It has been noted that
exosomes are able to penetrate the
most difficult of barriers, including the
blood-brain barrier (Batrakova & Kim,
2015). However, a paper by Riau et al.
(2019) highlighted the concerns regard-
ing the sustained release of administered
exosomes. When exosomes were
injected, they were cleared from the
blood circulation and accumulated in
the liver, spleen, lung and gastrointesti-
nal tract after only two hours. Topical
application of exosomes poses the same
concerns but are likely to clear at a
much rapid rate due to the fluid turn-
over of tears or sweat. Moreover, with
the variation in exosome extraction and
purification, it may not be possible to
mass produce exosomes that are of
good quality to allow for continued
administration to induce therapeutic
effects (Ayala-Mar et al. 2019). There-
fore, to facilitate treatment with smaller
quantities of exosomes, it has been
suggested to embed exosomes into
hydrogel matrices to facilitate a sus-
tained release and to prevent premature
clearance, leading to a more localized
and concentrated dosage at the target
site. This can act as a promising solu-
tion to overcome the large quantities of
exosomes required to elicit a therapeutic
response (Riau et al. 2019).
As exosome technology is emerging,
there is an element of experimental
approach when extracting exosomes
from various sources. Ludwig et al.
(2019) concluded that currently there is
no gold standard in exosome isolation,
therefore, variation in isolation tech-
nique may influence the findings of
studies using exosome therapies. In addi-
tion, there is also an unmet need for
standardizing exosome quality and min-
imum standards of requirement before it
can be clinically administered for treat-
ment in patients (Xu et al. 2020).
Furthermore, underpinning the
exact mechanisms by which many of
these ocular diseases progress is imper-
ative so that drugs can be created to
target specific pathways. As exosomes
are critical in cell-to-cell communica-
tion, understanding how the miRNA
cargo differs in healthy and affected
individuals may highlight key differ-
ences and potential prominent path-
ways of action. Hence, the approach to
extract exosomes to identify key
biomarkers could determine whether
it may be beneficial to upregulate or
downregulate specific pathways. Many
ocular diseases are polygenic and are,
therefore, influenced by many path-
ways. In glaucoma, some of the key
pathways include TGF-b signalling,
Phosphatase and Tensin Homologue
(PTEN) Pathway and Rho Kinase,
which can be activated by a variety of
factors including Wnt (Gauthier & Liu,
2017). While the studies discussed in this
review highlighted the impact of natu-
rally occurring miRNAs, exosomes pre-
sent an opportunity to be modified and
used as an organic nanovesicle. There is
a potential to create exosomes with
modifications, such as additional regu-
lating molecules like siRNAs, to further
enhance the existing benefits of exosome
therapies (Fernando et al. 2018; Gupta
et al. 2021; Sanghani et al. 2021).
Another approach could also be to
create nanovesicles with targeting moi-
eties (Tagalakis et al. 2017) and the
addition of natural glycosides (Weng
et al. 2015) that could increase the
uptake of exosomes in the cells of
interest and promote the release of their
cargos into the cytoplasm.
While interest in this field continues
to grow, we require further in-depth
in vivo studies that may translate into
human clinical trials. As highlighted
above, to our knowledge, there is
currently only one clinical trial
underway but we expect this number
to grow in the future. It would also be
interesting to compare if the elicited
therapeutic effects of exosome thera-
pies are an improvement to current
treatment options available to patients
and which treatment option offers the
best long-term prospects in reducing
ocular diseases.
Conclusion
Currently, the possibility of exploring
exosome therapies to overcome oph-
thalmological diseases proves to be a
promising field. However, it is yet to be
determined whether these therapeutic
effects can be replicated in human
clinical trials. If these prove successful,
it should be investigated whether they
will have the same long-term desirable
outcomes and minimal adverse effects.
There is also a need to standardize the
techniques associated with exosome
extraction and to determine a universal
standard of exosome quality before any
form of exosome therapy can be
offered to patients with ocular diseases.
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